Saturday, August 15, 2026 | 07:34 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Page 15 - Stock Analysis

HDFC Sec turns bullish on Dr Lal PathLabs; upgrades to 'Buy'; raises target

Dr Lal PathLabs is focusing on innovation, including new wellness packages and high-end, super-speciality tests, with a focus on capturing prescription shares

HDFC Sec turns bullish on Dr Lal PathLabs; upgrades to 'Buy'; raises target
Updated On : 31 Dec 2025 | 2:17 PM IST

Mirae Asset Sharekhan bullish on Lemon Tree on strong pipeline, RevPAR

Lemon Tree Hotels management has guided for mid-teens revenue growth driven by a busy wedding season, surge in MICE activities, higher share from Aurika, Mumbai and contribution from new hotels

Mirae Asset Sharekhan bullish on Lemon Tree on strong pipeline, RevPAR
Updated On : 31 Dec 2025 | 2:12 PM IST

Motilal Oswal bullish on VA Tech Wabag; strong order book supports growth

On the bourses, VA Tech Wabag share price rose as much as 6.17 per cent to an intraday high of ₹1,349, before trading 2.81 per cent higher at ₹1,306.20 around 12:50 PM.

Motilal Oswal bullish on VA Tech Wabag; strong order book supports growth
Updated On : 31 Dec 2025 | 12:51 PM IST

Brokerages raise target on Shriram Finance post analyst call; details here

Management emphasised that MUFG is being onboarded as a long-term strategic partner, bringing not only significant capital support but also meaningful value addition through funding diversification

Brokerages raise target on Shriram Finance post analyst call; details here
Updated On : 31 Dec 2025 | 11:46 AM IST

V-Mart's turnaround gathers pace as margins rise, stores scale up: Analysts

After three years of store rationalisation and pricing corrections, Unlimited's newer stores are now performing in line with core V-Mart outlets.

V-Mart's turnaround gathers pace as margins rise, stores scale up: Analysts
Updated On : 31 Dec 2025 | 9:44 AM IST

Ajanta Pharma shares up 3% as Biocon tie-up fuels long-term growth optimism

Ajanta Pharma shares gained 3% despite a weak market as analysts turned bullish on its Biocon partnership, semaglutide opportunity, and growth outlook

Ajanta Pharma shares up 3% as Biocon tie-up fuels long-term growth optimism
Updated On : 30 Dec 2025 | 11:33 AM IST

HDFC Sec upgrades Max Healthcare on strong expansion-led growth outlook

On the bourses, however, Max Healthcare share price was trading 1.75 per cent lower at ₹1,044.75 per share around 11:30 AM. By comparison, BSE Sensex was trading 0.07 per cent lower at 84,637.50.

HDFC Sec upgrades Max Healthcare on strong expansion-led growth outlook
Updated On : 30 Dec 2025 | 11:31 AM IST

Motilal Oswal stays bullish on Indigo Paints, bets on demand recovery

The brokerage has reiterated its 'Buy' rating on the stock, with a revised target price of ₹1,450, valuing the company at 35x Dec'27E earnings.

Motilal Oswal stays bullish on Indigo Paints, bets on demand recovery
Updated On : 30 Dec 2025 | 9:44 AM IST

Skipper newly rated 'Buy' at Systematix; 17% upside potential seen

Skipper is among the top 10 transmission tower manufacturers globally and has built a strong cost advantage through high backward integration, sourcing nearly 90 per cent of its raw materials in-house

Skipper newly rated 'Buy' at Systematix; 17% upside potential seen
Updated On : 30 Dec 2025 | 9:13 AM IST

What does Coforge's Encora acquisition mean for investors? Analysts weigh

Brokerages see the acquisition as aligned with Coforge's stated ambition to shift more deeply into higher-value, AI-driven engineering services

What does Coforge's Encora acquisition mean for investors? Analysts weigh
Updated On : 29 Dec 2025 | 12:37 PM IST

Lenskart: Emkay Global sees 6x revenue growth potential, initiates 'Buy'

Lenskart stock gets 'Buy' rating from Emkay Global with ₹525 target as brokerage highlights market leadership, tech edge and strong growth outloo

Lenskart: Emkay Global sees 6x revenue growth potential, initiates 'Buy'
Updated On : 29 Dec 2025 | 12:12 PM IST

Axis Bank's growth improving; NIMs to bottom in Q4FY26/Q1: Motilal Oswal

The brokerage has reiterated its 'Neutral' rating on the stock with a target price of ₹1,300 after its interaction with the top management team of Axis Bank

Axis Bank's growth improving; NIMs to bottom in Q4FY26/Q1: Motilal Oswal
Updated On : 29 Dec 2025 | 10:24 AM IST

Ashok Leyland set to ride CV upcycle; Choice hikes target, retains 'Buy'

The brokerage believes Ashok Leyland is poised to be a major beneficiary of India's ongoing commercial vehicle (CV) upcycle, helped by firming domestic demand, rising exports

Ashok Leyland set to ride CV upcycle; Choice hikes target, retains 'Buy'
Updated On : 26 Dec 2025 | 2:39 PM IST

Is Northern Arc your next growth stock? Ambit says 'Buy', 30% upside eyed

Northern Arc's long experience in finance placement and fund management should support fee income, helping absorb structurally higher credit costs, analysts at Ambit said

Is Northern Arc your next growth stock? Ambit says 'Buy', 30% upside eyed
Updated On : 26 Dec 2025 | 12:06 PM IST

Mirae Asset Sharekhan sees upside for Lodha on launches, Palava push

On the bourses, meanwhile, Lodha Developers share price was trading 0.09 per cent lower at ₹1,078.40 per share around 10:50 AM. By comparison, BSE Sensex was trading 0.21 per cent lower at 85,226.75.

Mirae Asset Sharekhan sees upside for Lodha on launches, Palava push
Updated On : 26 Dec 2025 | 11:05 AM IST

Motilal Oswal sees strong growth visibility for Brigade Ent; retains 'Buy'

Motilal Oswal believes Brigade Enterprises is now entering a new phase of geographic and asset-class expansion, led by fresh residential, commercial and hospitality bets beyond its Bengaluru core

Motilal Oswal sees strong growth visibility for Brigade Ent; retains 'Buy'
Updated On : 26 Dec 2025 | 10:00 AM IST

Ajanta Pharma to generate healthy margins from Biocon deal: PL Capital

According to PL Capital, Ajanta Pharma's strong franchise will aid in garnering a higher market share for semaglutide

Ajanta Pharma to generate healthy margins from Biocon deal: PL Capital
Updated On : 26 Dec 2025 | 8:49 AM IST

Margins, valuation hurdles for Eicher Motors despite strong volume gains

Royal Enfield's growth was primarily driven by the strong demand for Bullet 350 which saw a volume gain of 59 per cent Y-o-Y on a YTD basis

Margins, valuation hurdles for Eicher Motors despite strong volume gains
Updated On : 25 Dec 2025 | 11:36 PM IST

PL Capital hikes Adani Ports target on NQXT acquisition; retains 'Buy'

PL Capital maintained 'Buy' as it builds in stronger volumes and margins following the acquisition of North Queensland Export Terminal (NQXT)

PL Capital hikes Adani Ports target on NQXT acquisition; retains 'Buy'
Updated On : 24 Dec 2025 | 1:37 PM IST

Antique reaffirms 'Buy' on Jindal Steel; expects expansions to fuel profit

The brokerage believes that cost efficiencies from increased captive coal, a slurry pipeline, and higher captive power generation will support margins

Antique reaffirms 'Buy' on Jindal Steel; expects expansions to fuel profit
Updated On : 24 Dec 2025 | 12:48 PM IST